STAT+: Novo nears release of high-stakes data on Alzheimer’s and GLP-1sSTAT+: Novo nears release of high-stakes data on Alzheimer’s and GLP-1s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we report on how lawsuits linked to Covid-19 are gaining prominence under the Trump administration. We also await Novo results on GLP-1 effects on Alzheimer’s, and more. The need-to-know this morning Alkermes increased Read More
‘Traumatic wait’ for women facing breast cancer diagnoses’Traumatic wait’ for women facing breast cancer diagnoses
Dr Jilly O’Hagan says she is “hugely concerned” after three patients in her surgery received a late cancer diagnosis.
STAT+: Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key resultsSTAT+: Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results
Within the next two weeks, Novo Nordisk is expected to announce the results of perhaps the most ambitious studies yet of its blockbuster GLP-1 drug semaglutide — whether the medicine can help slow the progression of Alzheimer’s disease. The Danish company has repeatedly stressed that these are risky studies, since there hasn’t yet been definitive Read More
How to keep Ozempic/Wegovy weight loss without the nauseaHow to keep Ozempic/Wegovy weight loss without the nausea
Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may help create treatments that keep the benefits of weight loss while reducing unwanted side effects. Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that Read More
AI tool mimics pathologists to improve breast cancer tissue analysis accuracyAI tool mimics pathologists to improve breast cancer tissue analysis accuracy
A research team led by two University of Maine Ph.D. students developed an artificial intelligence (AI) system that could make it easier and faster for doctors to identify signs of breast cancer in tissue samples, possibly preventing delays and saving lives.
STAT+: Novo Nordisk’s $199 Ozempic deal shows what telehealth platforms can do for pharmaSTAT+: Novo Nordisk’s $199 Ozempic deal shows what telehealth platforms can do for pharma
On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to $199 when patients pay cash through Novo’s pharmacy NovoCare. Patients searching for those deals online, though, won’t always get funneled to the drugmaker’s sites. Instead, the first results they may Read More
Brain Activity on Zepbound; Alzheimer’s and Chris Hemsworth; Autism-Gut Link QueriedBrain Activity on Zepbound; Alzheimer’s and Chris Hemsworth; Autism-Gut Link Queried
(MedPage Today) — Intracranial electroencephalography measured the brain activity of a patient with obesity and loss-of-control eating after taking tirzepatide (Zepbound), showing the medication suppressed brain signaling associated with food… (MedPage Today) — Intracranial electroencephalography measured the brain activity of a patient with obesity and loss-of-control eating after taking tirzepatide (Zepbound), showing the medication Read More
Drug Cuts Nausea From GLP-1 Drugs; ‘Female Viagra’ Boom; Semaglutide and Alcohol UseDrug Cuts Nausea From GLP-1 Drugs; ‘Female Viagra’ Boom; Semaglutide and Alcohol Use
(MedPage Today) — Vanda Pharmaceuticals said its investigational neurokinin-1 receptor antagonist tradipitant reduced nausea and vomiting from semaglutide (Ozempic, Wegovy) in a randomized trial of people with obesity or overweight. A KFF poll… (MedPage Today) — Vanda Pharmaceuticals said its investigational neurokinin-1 receptor antagonist tradipitant reduced nausea and vomiting from semaglutide (Ozempic, Wegovy) in Read More
Breast Cancer and Birth Control: A Huge New Study Shows How Science Can Be DistortedBreast Cancer and Birth Control: A Huge New Study Shows How Science Can Be Distorted
(MedPage Today) — As misinformation about women’s health spreads faster than ever, doctors say new research on the risks of hormonal birth control underscores the challenge of communicating nuance in the social media age.
The massive study, which…
Navigating Second-Line Endocrine Options in Breast CancerNavigating Second-Line Endocrine Options in Breast Cancer
(MedPage Today) — The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is becoming increasingly complex, with decisions now shaped by ESR1 and PIK3CA mutations, CDK4/6 inhibitor exposure…